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We would like to thank the contributing authors Manson 
et al1 for their article “Identification of Sonographic B-Lines 
with Linear Transducer Predicts Elevated B-Type Natriuretic 
Peptide Level.”By attempting to validate this easily learned 
and reproducible ultrasound technique, they have contributed 
to the growing body of research that suggests bedside thoracic 
ultrasound can provide rapid point-of-care testing to help 
guide the diagnosis of congestive heart failure (CHF) in the 
emergency department (ED).2
The rapid diagnosis of CHF in ED patients with 
undifferentiated dyspnea remains a challenge.  Although we 
have a multitude of clinical information that suggests heart 
failure, no single aspect of the history, physical examination, 
echocardiogram, chest radiograph or blood chemistry is 
specific or sensitive enough to rule in or out the diagnosis.3 
Rather, clinicians must incorporate all of this data into their 
clinical assessment. Decision scores such as the Framingham 
and Boston criteria have been developed as systematic ways 
of weighing such data against the probability of CHF.4,5
B-type Natriuretic Peptide (BNP) is an important tool 
amongst these diagnostic modalities. Multiple studies have 
demonstrated its effectiveness, particularly its ability to help 
rule out the diagnosis of CHF when levels are below cutoff 
values (typically 100). This high negative predictive value is 
often used in the ED to distinguish dyspnea caused by heart 
failure from exacerbations of chronic obstructive pulmonary 
disease.6  
It is important to remember, however, that BNP is not 
to be used as a stand-alone test. Multiple factors besides 
CHF can contribute to an elevated BNP level. These include 
advanced age, renal failure, acute coronary syndromes and 
atrial fibrillation.7,8 BNP levels between 100 and 500 pg/
ml fall into a range that are less helpful in excluding or 
confirming the diagnosis. Therefore, any interpretation of BNP 
should be made only after the clinician has established the pre-
test probability of CHF using all available clinical data. 
 Just as an isolated BNP value is unacceptable as proof 
of diagnosis of CHF in clinical practice, so too is its use as a 
lone diagnostic standard in the research setting. The research 
submitted by Manson et al. does not attempt to validate 
bedside ultrasound as a means of differentiating CHF. Rather 
they test the ability of ultrasound to predict a cutoff value of 
BNP, a surrogate for the diagnosis. As a result, we are left with 
a correlation between ultrasound findings and lab values—
each one of which must be interpreted with the corresponding 
patient’s clinical presentation if it is to accurately suggest 
CHF.
If we are to validate such techniques in the future, we 
must use more accurate methods in establishing the diagnosis 
of CHF. Because there is no single sufficient diagnostic 
criterion, the research standard of diagnosing CHF should be 
the same as those in clinical practice—namely, the judgment 
of physicians. Prospective studies that include retrospective 
review by a panel of physicians, considering all presenting 
signs, symptoms, and diagnostic data of the subject in 
question, are the most widely accepted and reasonable basis 
of establishing the diagnosis of CHF. Although such methods 
are costly and time consuming, they should be considered the 
criterion standard for further research. 
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